Drug Profile
Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen
Latest Information Update: 27 Sep 2010
Price :
$50
*
At a glance
- Originator DeveloGen
- Class Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Sep 2010 DeveloGen has been acquired by Evotec AG
- 21 Jun 2007 Teva Pharmaceutical Industries granted an exclusive worldwide license to DeveloGen's protein kinase B technology for the treatment of cancer
- 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen